{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:58:32Z","timestamp":1780865912482,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jpsychires.2025.12.046","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:05:54Z","timestamp":1766534754000},"page":"99-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparison of premenstrual dysphoric disorder treatment with antidepressants and combined oral contraceptives: a systematic review with network meta-analysis"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7762-2591","authenticated-orcid":false,"given":"Luigi Chermont","family":"Berni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia Ribeiro","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita de C\u00e1ssia Silva de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jpsychires.2025.12.046_bib1","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/AOG.0000000000005426","article-title":"Management of premenstrual disorders. ACOG clinical practice guideline No. 7","volume":"142","year":"2023","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jpsychires.2025.12.046_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.jpsychires.2025.12.046_bib3","article-title":"Comparison of the treatment of premenstrual dysphoric disorder with antidepressants and combined oral contraceptives: a systematic review with network meta-analysis [internet]","author":"Berni","year":"2024","journal-title":"PROSPERO"},{"key":"10.1016\/j.jpsychires.2025.12.046_bib4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2147\/IJWH.S297062","article-title":"Management of premenstrual dysphoric disorder: a scoping review","volume":"14","author":"Carlini","year":"2022","journal-title":"Int. J. Wom. Health"},{"issue":"5","key":"10.1016\/j.jpsychires.2025.12.046_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.psy.0000140005.94790.9c","article-title":"Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial","volume":"66","author":"Cohen","year":"2004","journal-title":"Psychosom. Med."},{"issue":"10","key":"10.1016\/j.jpsychires.2025.12.046_bib6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/da.22673","article-title":"Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: results of a three-arm randomized controlled trial","volume":"34","author":"Eisenlohr-Moul","year":"2017","journal-title":"Depress. Anxiety"},{"issue":"2","key":"10.1016\/j.jpsychires.2025.12.046_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/JCP.0b013e3181678a28","article-title":"Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder","volume":"28","author":"Eriksson","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.jpsychires.2025.12.046_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.contraception.2011.09.010","article-title":"An overview of four studies of a continuous oral contraceptive (Levonorgestrel 90 mcg\/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome","volume":"85","author":"Freeman","year":"2012","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.jpsychires.2025.12.046_bib9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/AOG.0b013e318236edf2","article-title":"Clinical subtypes of premenstrual syndrome and responses to sertraline treatment","volume":"118","author":"Freeman","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jpsychires.2025.12.046_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jad.2024.10.020","article-title":"Intermittent escitalopram treatment and reactive aggression in women with premenstrual irritability and anger: a crossover study","volume":"369","author":"Gr\u00f6ndal","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"7","key":"10.1016\/j.jpsychires.2025.12.046_bib11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1017\/S1092852900016849","article-title":"Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough","volume":"13","author":"Halbreich","year":"2008","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.12.046_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.contraception.2011.05.008","article-title":"Continuous oral levonorgestrel\/ethinyl estradiol for treating premenstrual dysphoric disorder","volume":"85","author":"Halbreich","year":"2012","journal-title":"Contraception"},{"issue":"11","key":"10.1016\/j.jpsychires.2025.12.046_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11920-015-0628-3","article-title":"Premenstrual dysphoric disorder: epidemiology and treatment","volume":"17","author":"Hantsoo","year":"2015","journal-title":"Curr. Psychiatry Rep."},{"issue":"2","key":"10.1016\/j.jpsychires.2025.12.046_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00213-006-0607-9","article-title":"Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests","volume":"190","author":"Inoue","year":"2007","journal-title":"Psychopharmacology (Berl.)"},{"issue":"1","key":"10.1016\/j.jpsychires.2025.12.046_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.npp.1301216","article-title":"Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder","volume":"32","author":"Land\u00e9n","year":"2007","journal-title":"Neuropsychopharmacology: Offc. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.jpsychires.2025.12.046_bib16","first-page":"613","article-title":"Premenstrual dysphoric disorder","volume":"103","author":"Lanza di Scalea","year":"2019","journal-title":"Med. Clin."},{"key":"10.1016\/j.jpsychires.2025.12.046_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.psyneuen.2016.11.033","article-title":"Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial","volume":"76","author":"Lundin","year":"2017","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"10.1016\/j.jpsychires.2025.12.046_bib18","article-title":"Oral contraceptives containing drospirenone for premenstrual syndrome","volume":"6","author":"Ma","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.jpsychires.2025.12.046_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nn1469","article-title":"Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety","volume":"8","author":"Maguire","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"4753","key":"10.1016\/j.jpsychires.2025.12.046_bib20","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1126\/science.2422758","article-title":"Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor","volume":"232","author":"Majewska","year":"1986","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jpsychires.2025.12.046_bib21","article-title":"Selective serotonin reuptake inhibitors for premenstrual syndrome","volume":"2013","author":"Marjoribanks","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.jpsychires.2025.12.046_bib22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1517\/14656566.9.4.517","article-title":"Duloxetine for premenstrual dysphoric disorder: a pilot study","volume":"9","author":"Mazza","year":"2008","journal-title":"Expet Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.jpsychires.2025.12.046_bib23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0306-4530(02)00033-1","article-title":"Serotonin transporter gene polymorphisms and platelet [3H] paroxetine binding in premenstrual dysphoria","volume":"28","author":"Melke","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jpsychires.2025.12.046_bib24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"issue":"3","key":"10.1016\/j.jpsychires.2025.12.046_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1783\/147118909788708147","article-title":"Management of premenstrual syndrome","volume":"35","author":"Panay","year":"2009","journal-title":"J. Fam. Plann. Reprod. Health Care"},{"issue":"6","key":"10.1016\/j.jpsychires.2025.12.046_bib26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.contraception.2005.08.021","article-title":"Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation","volume":"72","author":"Pearlstein","year":"2005","journal-title":"Contraception"},{"issue":"8","key":"10.1016\/j.jpsychires.2025.12.046_bib27","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1017\/S1461145709000066","article-title":"Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial","volume":"12","author":"Ramos","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.jpsychires.2025.12.046_bib28","first-page":"533","article-title":"Whole-blood serotonin in premenstrual syndrome","volume":"70","author":"Rapkin","year":"1987","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jpsychires.2025.12.046_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.704488","article-title":"Pilot data on the feasibility and clinical outcomes of a nomegestrol acetate oral contraceptive pill in women with premenstrual dysphoric disorder","volume":"12","author":"Robertson","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"4","key":"10.1016\/j.jpsychires.2025.12.046_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM199801223380401","article-title":"Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome","volume":"338","author":"Schmidt","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jpsychires.2025.12.046_bib31","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/AOG.0b013e31816fd73b","article-title":"Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis","volume":"111","author":"Shah","year":"2008","journal-title":"Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.jpsychires.2025.12.046_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neuropharm.2005.04.026","article-title":"Short-term steroid treatment increases Delta GABAA receptor subunit expression in rat CA1 hippocampus: pharmacological and behavioral effects","volume":"49","author":"Shen","year":"2005","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.jpsychires.2025.12.046_bib33","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/da.21959","article-title":"Rapid response to fluoxetine in women with premenstrual dysphoric disorder","volume":"29","author":"Steinberg","year":"2012","journal-title":"Depress. Anxiety"},{"issue":"2","key":"10.1016\/j.jpsychires.2025.12.046_bib34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ajog.2005.01.021","article-title":"Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder","volume":"193","author":"Steiner","year":"2005","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.jpsychires.2025.12.046_bib35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1471-0528.2001.00120.x","article-title":"The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder","volume":"108","author":"Steiner","year":"2001","journal-title":"BJOG An Int. J. Obstet. Gynaecol."},{"issue":"23","key":"10.1016\/j.jpsychires.2025.12.046_bib36","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM199506083322301","article-title":"Fluoxetine in the treatment of premenstrual dysphoria. Canadian fluoxetine\/premenstrual dysphoria collaborative study group","volume":"332","author":"Steiner","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpsychires.2025.12.046_bib37","author":"Sterne"},{"issue":"1","key":"10.1016\/j.jpsychires.2025.12.046_bib38","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ [Internet]"},{"issue":"3","key":"10.1016\/j.jpsychires.2025.12.046_bib39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1176\/appi.prcp.20220007","article-title":"Significance and interrelationship of the symptoms listed in the DSM criteria for premenstrual dysphoric disorder","volume":"5","author":"Studer","year":"2023","journal-title":"Psychiatric Research Clinical Pract."},{"issue":"5","key":"10.1016\/j.jpsychires.2025.12.046_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40263-023-01004-9","article-title":"New pharmacological approaches to the management of premenstrual dysphoric disorder","volume":"37","author":"Sundstr\u00f6m-Poromaa","year":"2023","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.jpsychires.2025.12.046_bib41","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jog.15484","article-title":"Premenstrual disorders: premenstrual syndrome and premenstrual dysphoric disorder","volume":"49","author":"Takeda","year":"2023","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"10","key":"10.1016\/j.jpsychires.2025.12.046_bib42","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/jog.12774","article-title":"Effectiveness of ethinylestradiol\/drospirenone for premenstrual symptoms in Japanese patients with dysmenorrhea: open-label pilot study","volume":"41","author":"Takeda","year":"2015","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.jpsychires.2025.12.046_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.12703\/r\/11-11","article-title":"Recent advances in understanding\/management of premenstrual dysphoric disorder\/premenstrual syndrome","volume":"11","author":"Tiranini","year":"2022","journal-title":"Faculty Rev."},{"issue":"6","key":"10.1016\/j.jpsychires.2025.12.046_bib44","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ajog.2021.06.090","article-title":"Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials","volume":"225","author":"Wit","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.12.046_bib45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1440-1819.2007.01785.x","article-title":"Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols","volume":"62","author":"Wu","year":"2008","journal-title":"Psychiatr. Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.jpsychires.2025.12.046_bib46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/JCP.0000000000001700","article-title":"Does symptom-onset treatment with sertraline improve functional impairment for individuals with premenstrual dysphoric disorder?: a randomized controlled trial","volume":"43","author":"Yonkers","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.jpsychires.2025.12.046_bib47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/01.AOG.0000175834.77215.2e","article-title":"Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder","volume":"106","author":"Yonkers","year":"2005","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.jpsychires.2025.12.046_bib48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/01.jcp.0000203197.03829.ae","article-title":"Symptom-onset treatment for women with premenstrual dysphoric disorder","volume":"26","author":"Yonkers","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.jpsychires.2025.12.046_bib49","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jamapsychiatry.2015.1472","article-title":"Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial","volume":"72","author":"Yonkers","year":"2015","journal-title":"JAMA Psychiatry"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625007939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625007939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:01:05Z","timestamp":1780862465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395625007939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":49,"alternative-id":["S0022395625007939"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.12.046","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of premenstrual dysphoric disorder treatment with antidepressants and combined oral contraceptives: a systematic review with network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.12.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}